

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1(Currently amended). A monoclonal IgG antibody (Mab) capable of binding Placental Protein 13 (PP-13) ~~with high affinity~~ and of detecting PP-13 at a concentration of 10 pg/ml in a sandwich ELISA assay.

2(Currently amended). [[A]] The Mab according to Claim 1 produced by a hybridoma cell selected from the group consisting of clones #26-2, 27-2-3, 215-28-3, 534-16 and 606-8-11-67 deposited under accession nos. I-2134, I-2135, I-2136, I-2137, and I-2138.

3(Currently amended). A hybridoma ~~clone~~ selected from the group consisting of clones ~~#26-2, 27-2-3, 215-28-3, 534-16 and 606-8-11-67~~ deposited under accession nos. I-2134, I-2135, I-2136, I-2137 and I-2138.

4(Currently amended). An immunoassay for measuring the level of PP-13 in a biological fluid, comprising the steps of:

~~One~~ (a) bringing said fluid into contact with a Mab according to any of Claims 1, 2, or ~~[[16]]~~ 18, thereby forming Mab-PP-13 complexes;

~~Two~~ (b) exposing said complexes to a second Mab according to any of claims 1, 2, or ~~[[16]]~~ 18 linked to a signal-generating molecule, said second Mab being capable of binding said complexes; and

~~Three~~ (c) providing conditions conducive to the production of a signal generated by said signal-generating molecule, the level of said signal indicating the level of PP-13 in the biological fluid,

wherein said immunoassay is capable of measuring PP-13 ~~over~~ at a concentration ~~range~~ of 10-500 pg/ml.

5 (Currently amended). ~~[[An]]~~ The immunoassay according to Claim 4, wherein said Mab in step (a) is bound to a solid phase.

Claim 6 (Cancelled).

7 (Currently amended). ~~[[An]]~~ The immunoassay according to ~~either of Claims 4 or 5~~ Claim 4, wherein said signal generating molecule is an enzyme.

8(Currently amended). [[An]] The immunoassay according to ~~either of Claims 4 or 5~~ Claim 4, wherein said signal generating molecule is a ligand, and step (c) of Claim 4 comprises incubating the product of step (b) with a ligand binding molecule linked to an enzyme.

9(Currently amended). A kit for measuring the level of PP-13 in a biological fluid, comprising:

- (a) a Mab according to Claim 1;
- (b) a second antibody linked to a signal-generating molecule, wherein said second antibody is also a Mab according to Claim 1; and
- (c) PP-13 standard solutions.

10(Currently amended). A kit for measuring the level of PP-13 in a biological fluid, comprising:

- ~~One~~ (a) a Mab according to any of Claims 1, 2, or [[16]] 18;
- ~~Two~~ (b) a second Mab according to any of Claims 1, 2, or [[16]] 18 linked to a signal-generating molecule; and
- ~~Three~~ (c) PP-13 standard solutions.

11(Currently amended). [[A]] The kit according to Claim 9, wherein said signal generating molecule is an enzyme.

Claim 12 (Cancelled)

13(Currently amended). [[A]] The kit according to Claim [[12]] 9, wherein said signal-generating molecule ~~ligand~~ is biotin and ~~said ligand binding molecule is~~ the kit further comprises extravidin linked to an enzyme.

14(Previously presented). A Mab according to Claim 1, capable of detecting PP-13 at a concentration of 0.05 ng/ml in a sandwich ELISA assay.

15(Currently amended). [[A]] The kit according to Claim 11, wherein said signal generating molecule is an enzyme.

16(Currently amended). [[A]] The kit according to Claim 11, wherein said signal generating molecule is a ligand, and said kit further comprises a ligand binding molecule linked to an enzyme.

17(Currently amended). [[A]] The kit according to Claim 16, wherein said ligand is biotin and said ligand-binding molecule is extravidin.

18(New). The Mab according to Claim 2 produced by the hybridoma clone deposited under accession no. I-2135 or I-2136.

Appln. No. 09/937,706

Amd. dated February 4, 2004

Reply to Office Action of October 14, 2003

19(New). The immunoassay according to Claim 5, wherein said signal generating molecule is an enzyme.